



Medical Microbiology

Detection and analysis of different interactions between resistance mechanisms and carbapenems in clinical isolates of *Klebsiella pneumoniae*



Tanise Vendruscolo Dalmolin^a, Bianca Vendruscolo Bianchini^a, Grazielle Guidolin Rossi^a, Ana Carolina Ramos^b, Ana Cristina Gales^b, Priscila de Arruda Trindade^{a,*}, Marli Matiko Anraku de Campos^a

^a Universidade Federal de Santa Maria (UFSM), Laboratório de Micobacteriologia, Santa Maria, RS, Brazil

^b Universidade Federal de São Paulo (UNIFESP), Laboratório ALERTA, São Paulo, SP, Brazil

ARTICLE INFO

Article history:

Received 6 April 2016

Accepted 6 January 2017

Available online 9 February 2017

Associate Editor: Afonso Barth

Keywords:

Klebsiella pneumoniae

Carbapenemases

Loss of porins

Eflux pump

ABSTRACT

Carbapenems are considered last-line agents for the treatment of serious infections caused by *Klebsiella pneumoniae*, and this microorganism may exhibit resistance to β -lactam antibiotics due to different mechanisms of resistance. We evaluated 27 isolates of *K. pneumoniae* resistant to carbapenems recovered from inpatients at the University Hospital of Santa Maria-RS from July 2013 to August 2014. We carried out antimicrobial susceptibility, carbapenemase detection, testing for the presence of efflux pump by broth microdilution and loss of porin by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Genetic similarity was evaluated by ERIC-PCR. High levels of resistance were verified by the minimum inhibitory concentration for the antimicrobials tested. The *bla_{KPC}* gene was present in 89% of the clinical isolates. Blue-Carba and combined disk with AFB tests showed 100% concordance, while the combined disk test with EDTA showed a high number of false-positives (48%) compared with the gold-standard genotypic test. Four isolates showed a phenotypic resistance profile consistent with the overexpression of the efflux pump, and all clinical isolates had lost one or both porins. The ERIC-PCR dendrogram demonstrated the presence of nine clusters. The main mechanism of resistance to carbapenems found in the assessed isolates was the presence of the *bla_{KPC}* gene.

© 2017 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author at: Avenida Roraima, no. 1000, Brazil.

E-mail: priscila.trindade@gmail.com (P.A. Trindade).

<http://dx.doi.org/10.1016/j.bjm.2017.01.003>

1517-8382/© 2017 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Cephalosporins used to be the antibiotics commonly prescribed for treatment of severe *Klebsiella pneumoniae* infections. However, due to the high frequency of extended spectrum β -bactamases (ESBL) producing *K. pneumoniae*, carbapenems have become the most common antibiotics prescribed for the treatment of these infections. Unfortunately, the high consumption of carbapenems has been accompanied by the emergence and spread of carbapenem-resistant *K. pneumoniae*.¹

Resistance to carbapenems can be associated with the production of carbapenemases, loss of porins and overexpression of the efflux pump. *K. pneumoniae* have acquired genes encoding for carbapenemases, which are enzymes capable of breaking down most β -lactams antibiotics, including carbapenems, and thus conferring resistance to these drugs, which can result in treatment failure.² The carbapenemases are classified in A, B and D Ambler classes. The most common carbapenemase class A is *K. pneumoniae* carbapenemase (KPC), the most common carbapenemase class B is New Delhi metalo β -lactamase (NDM) and the most common carbapenemase class D is Oxacillinase-48 (OXA-48), occurring in *K. pneumoniae*.³

K. pneumoniae presents two main porins, OmpK35 and OmpK36. The loss of these porins (OmpK35 and OmpK36) may play an important role in the development of resistance to carbapenems in *K. pneumoniae*.⁴ Furthermore, overexpression of the AcrAB efflux pump has also been proposed as being responsible for reduced susceptibility to ertapenem and meropenem antibiotics in some strains.⁵

The aim of this study was to evaluate mechanisms involved in carbapenem resistance among *K. pneumoniae* isolates. As carbapenemases are most often acquired by horizontal transfer between strains, whereas change in carbapenem permeability or efflux is a result of point mutations, it is important to study these different resistance mechanisms in locally collected strains, as these resistance mechanism profiles might vary temporally and geographically.

Materials and methods

Bacterial strains

Twenty-seven non-duplicated *K. pneumoniae* clinical isolates resistant to carbapenems collected from July 2013 to August 2014 at the Santa Maria University Hospital, Brazil were included in this study. Species identification was carried out on the Vitek® 2 automated identification system (Biomérieux, France) and confirmed with MALDI-TOF MS in a Microflex LT apparatus (Bruker Daltonics, Germany) considering a score value between 2.0 and 2.299.⁶

Susceptibility testing

The antimicrobials used for susceptibility testing were imipenem, meropenem, ertapenem, cefepime, cefazidime, and cefoxitin. The tests were performed by broth

microdilution according to CLSI guidelines.⁷ *Escherichia coli* ATCC 25922 was used as a quality control.

Carbapenemases

The detection of genes *bla*_{KPC},⁸ *bla*_{OXA-48},⁹ and *bla*_{NDM},¹⁰ was carried out using the multiplex PCR technique, as well as the detection of genes *blasIM*, *bla*_{SPM}, *bla*_{IMP}, *bla*_{VIM} and *bla*_{GIM}.¹¹ The detection of *bla*_{GES} was carried out with simplex PCR.¹²

Disk diffusion assay using phenyl boronic acid, EDTA and cloxacillin

For phenotypic detection of the KPC- and metallo- β -lactamases (MBLs), we used disk diffusion assays with phenylboronic acid (AFB)¹³ and ethylenediamine tetra-acetic acid (EDTA), respectively.¹⁴ In both tests, an increase of 5 mm in zone diameter in the presence of AFB or EDTA compared with either meropenem or imipenem tested alone was considered to represent a positive result for the presence of KPC β -lactamase or MBL enzyme, respectively.

For the detection of plasmid-mediated AmpC, we used test results from AFB and cloxacillin (CLOXA)¹³ in combination with meropenem and imipenem, compared with carbapenem disks alone. An increase of 5 mm in zone diameter for both AFB and CLOXA was considered to be a positive test result for the presence of AmpC. Strains KPC2-*K. pneumoniae*, IMP1-*K. pneumoniae* and *E. coli* ATCC 25922 were used as quality controls.

Blue-Carba test

The Blue-Carba test consists of the detection of hydrolysis of the carbapenem β -lactam ring in a bacterial extract through the acidification of bromothymol blue indicator. A loop of a pure bacterial culture was directly suspended in 100 μ L of the test solution (aqueous solution of bromothymol blue, ZnSO₄ and imipenem) and in the negative-control solutions (without imipenem), followed by incubation at 37 °C for 2 h, with the first reading at 15 min. Carbapenemase activity was revealed when the test and negative-control solutions were (i) yellow versus blue, (ii) yellow versus green, or (iii) green versus blue. Noncarbapenemase producers remained blue or green on both solutions. Strains harboring the genes *bla*_{KPC}, *bla*_{IMP} and *bla*_{OXA-48} were used as positive controls, and *E. coli* ATCC 25922 was used as a negative control.¹⁵

Efflux pump

The technique was carried out by broth microdilution using antimicrobial alone and associated with the efflux pump inhibitor carbonyl cyanide m-chlorophenyl hydrazone (CCCP), using half of the minimal inhibition concentration (MIC) for CCCP. The reduction in MIC of the antimicrobial sample, associated with the efflux pump inhibitor, was indicative of efflux pump overproduction.¹⁶

OMP analysis

Outer membrane protein (OMP) profiles were analyzed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis

(SDS-PAGE).¹⁷ OmpK35 of *K. pneumoniae*, OmpK36 of *K. pneumoniae* and OmpK35 and OmpK36 of *K. pneumoniae* were used as control strains belonging to the Alerta Laboratory (UNIFESP).

Enterobacterial repetitive intergenic consensus sequences (ERIC-PCR)

ERIC-PCR was performed using 12.5 µL of MasterMix SYBR-Green (1×), 1 µL of DMSO (dimethyl sulfoxide), 2.5 µL of template, 1 µL from primer ERIC2 (AAGTAAGTGACTGGGG-TGAGCC)¹⁸ and water to complete the total volume of 25 µL. The PCR amplifications were performed in a thermocycler as follows: 94 °C for 10 min and 40 cycles of 30 s at 92 °C, 1 min at 52 °C and 8 min at 65 °C. A final extension step of 16 min at 65 °C was performed. ERIC-PCR fingerprint analysis was performed with BioNumerics 6.6 software (Applied Maths, Belgium), based on Dice's similarity coefficient and using unweighted-pair group method with arithmetic mean (UPGMA). Band position tolerance was 2.0%, and optimization was 0.8%. Isolates with a similarity coefficient ≥90% were considered to belong to the same cluster.¹⁹

Results

Twenty-four (89%) isolates were positive for the *bla_{KPC}* gene. The other carbapenemase genes investigated were not detected in the isolates. Among the KPC producing *K. pneumoniae*, the values of MIC₅₀ and MIC₉₀ demonstrate a high level of resistance for all antimicrobials tested (Table 1).

Tests for carbapenemase phenotypical and molecular detection, as well as overproduction of the efflux pump and porin loss, are shown in Table 2.

The 27 isolates of *K. pneumoniae* were grouped in nine different clusters, designated A, B, C, D, E, F, G, H and I as determined by ERIC-PCR (Fig. 1). The major group is A that included 14 isolates (52%), followed by group B with five isolates (19%) and group C with two isolates (7.4%). Clusters D, E, F, G, H and I had one isolate each.

Discussion

The class A *K. pneumoniae* carbapenemase (KPC) is one of the most common mechanisms of carbapenem resistance in Enterobacteriaceae. The KPC enzymes confer resistance to all β-lactam agents, including penicillins, cephalosporins, monobactams, and carbapenems.²⁰ In our study, when comparing carbapenem resistance level between the group that harbored the *bla_{KPC}* gene (group KPC) and isolates that tested negative for its presence (group non KPC), it was determined that the KPC enzyme probably could represent the main mechanism responsible for the high level of resistance to carbapenems observed among the isolates. All isolates presented a loss of one or both porins; therefore, this resistance mechanism can contribute to the high level of resistance observed in the non KPC group. The presence of efflux pump in some isolates of the KPC group did not change the high level of antibiotic resistance (data not shown).

The analysis of ERIC-PCR band patterns revealed a clonal spread at our institution. This finding is actually a global




Fig. 1 – Dendrogram generated from the ERIC-PCR profiles of 27 isolates of *K. pneumoniae*.

concern and is well documented in many hospitals, including other Brazilian hospitals.^{21–23} It will be interesting to submit the isolates to further analysis by pulsed-field electrophoresis and multilocus sequence typing to confirm the clonal relatedness observed among the carbapenem-resistant *K. pneumoniae*.

Methods for the phenotypic identification of carbapenemases are based on the use of specific inhibitors (AFB and EDTA) or in the detection of hydrolysis of the carbapenem β-lactam ring with an indicator. Both the phenotypic AFB-based method and Blue-Carba were 100% sensible and specific, considering PCR as the gold standard. Studies have shown that the sensitivity of the disk diffusion assay using AFB is 100%^{14,24} and the Blue-Carba test presents 100% specificity and sensitivity.¹⁵

The MBLs phenotypic detection test using EDTA presented a high false-positive rate (48%) when compared with the PCR technique, a fact that has also been reported in the literature.^{15,25–27} These results can be explained based on the

Table 1 – MIC 50 and 90 for antimicrobials tested against 27 clinical isolates of *Klebsiella pneumoniae*.

	KPC		Non KPC	
	MIC ₅₀ ($\mu\text{g/mL}$) ^a	MIC ₉₀ ($\mu\text{g/mL}$) ^b	MIC ₅₀ ($\mu\text{g/mL}$) ^a	MIC ₉₀ ($\mu\text{g/mL}$) ^b
Imipenem	32	>128	8	32
Ertapenem	>128	>128	16	16
Meropenem	128	>128	4	32
Cefepime	>128	>128	>128	>128
Ceftazidime	64	>128	64	>128
Cefoxitin	128	>128	64	128

^a MIC₅₀: concentration that inhibits 50% of bacterial isolates.^b MIC₉₀: concentration that inhibits 90% of bacterial isolates.**Table 2 – Phenotypic and genotypic characterization of the 27 *Klebsiella pneumoniae* isolates.**

Clinical isolates	Source	Efflux pump	OmpK35/36	Blue-Carba	CLOXA	EDTA	AFB	Cluster
1	Peritoneal fluid	POS ^a	Loss OmpK35 or OmpK36	POS	NEG ^b	NEG	POS	B
2	Urine	POS	Loss OmpK35 or OmpK36	POS	NEG	POS	POS	B
3	Sputum	NEG	Loss OmpK35 or OmpK36	POS	NEG	NEG	POS	I
4	Rectal Swab	POS	Loss OmpK35 and OmpK36	POS	POS	POS	POS	C
5	Urine	NEG	Loss OmpK35 or OmpK36	POS	NEG	NEG	POS	B
6	Urine	NEG	Loss OmpK35 or OmpK36	POS	NEG	NEG	POS	B
7	Others	NEG	Loss OmpK35 and OmpK36	POS	NEG	POS	POS	E
8	Blood	NEG	Loss OmpK35 and OmpK36	POS	NEG	NEG	POS	A
9	Urine	NEG	Loss OmpK35 and OmpK36	POS	NEG	NEG	POS	G
10	Stool	NEG	Loss OmpK35 or OmpK36	POS	POS	POS	POS	H
11	Urine	NEG	Loss OmpK35 or OmpK36	POS	NEG	POS	POS	D
12	Stool	NEG	Loss OmpK35 and OmpK36	POS	NEG	POS	POS	A
13	Others	NEG	Loss OmpK35 and OmpK36	POS	NEG	POS	POS	A
14	Stool	NEG	Loss OmpK35 and OmpK36	POS	NEG	POS	POS	A
15	Urine	NEG	Loss OmpK35 and OmpK36	POS	NEG	NEG	POS	A
16	Blood	NEG	Loss OmpK35 and OmpK36	POS	NEG	POS	POS	A
17	Wound	NEG	Loss OmpK35 and OmpK36	POS	NEG	POS	POS	A
18	Urine	NEG	Loss OmpK35 and OmpK36	POS	NEG	NEG	POS	A
19	Others	NEG	Loss OmpK35 and OmpK36	POS	NEG	POS	POS	A
20	Blood	NEG	Loss OmpK35 and OmpK36	POS	POS	POS	POS	A
21	Urine	NEG	Loss OmpK35 and OmpK36	POS	NEG	POS	POS	A
22	Rectal Swab	POS	Loss OmpK35 and OmpK36	POS	NEG	NEG	POS	A
23	Sputum	NEG	Loss OmpK35 and OmpK36	POS	NEG	NEG	POS	A
24	Others	NEG	Loss OmpK35 and OmpK36	POS	NEG	NEG	POS	A
25 ^c	Pleural	NEG	Loss OmpK35 and OmpK36	NEG	NEG	NEG	NEG	C
26 ^c	Tracheal aspirates	NEG	Loss OmpK35 or OmpK36	NEG	NEG	NEG	NEG	F
27 ^c	Stool	NEG	Loss OmpK35 or OmpK36	NEG	NEG	NEG	NEG	B

^a POS = positive.^b NEG = negative.^c Isolates non-KPC producing.

effect on membrane permeability, which can increase the susceptibility to many antimicrobial agents, including imipenem and meropenem.^{26,27} It can also be associated with a low production of β -lactamase or even with production of some unknown enzyme.²⁸ The high false-positive rates observed in this study could be due to the clonal nature of our isolates, as 61.5% of them belonged to cluster A. However, we found false-positive results among isolates belonging to clusters B, C, D, E and H.

In our collection, the absence of one or both porins (OmpK35 and OmpK36) was found in all the isolates. Due to the limitation of the SDS-PAGE technique and the very close molecular masses of the porins evaluated, we were not able to distinguish exactly which of the porins were absent.

The loss of the major porins OmpK35/36 is often observed in *K. pneumoniae* clinical isolates resistant to carbapenems, demonstrating an increase in MICs to cephalosporins and carbapenems. The loss of only the OmpK35 porin did not significantly influence the resistance to carbapenems.^{29,30} In contrast, the loss of OmpK35/36 conferred 31-, 8- and 4-fold increases in the MIC of ertapenem, meropenem and doripenem, respectively, and led to ertapenem resistance.¹ This suggests that when a clinical isolate from our study lost a porin, it was most likely OmpK36. However, additional molecular analysis will be needed to confirm this result. Clinical isolates tested against cephalosporins and carbapenems showed resistance, and the highest MIC values (>128 $\mu\text{g/mL}$) were associated with the loss of both porins (data not shown).

In our study, the active efflux mechanism was always associated with other mechanisms that had already been proven to participate in the resistance to carbapenems. This active efflux was found in isolates from clusters A, B and C, and thus further studies should be carried out to evaluate the overexpression and characterization of efflux pumps in these clusters. Nevertheless, the literature is controversial regarding the participation of active efflux in the resistance to carbapenems.³¹

In conclusion, the major mechanism related to carbapenem resistance that we found was the presence of the *bla_{KPC}* gene associated with porin loss. Different resistance mechanisms to carbapenems were present in clinical isolates, demonstrating that often the cause of resistance cannot be only a single mechanism but the combination of many. Our results showed that 14% of clinical isolates exhibit a combination of three different resistance mechanisms (carbapenemases, drug efflux and loss of porin). The detection of these mechanisms becomes extremely important for the implementation of infection control and prevention measures as well as epidemiological surveillance.

Conflicts of interest

Ana Cristina Gales has recently received research funding and/or consultation fees from AstraZeneca, MSD and Novartis. All the other authors declare no conflicts of interest.

Acknowledgments

Coordenação de Aperfeiçoamento de Pessoal do Ensino Superior (CAPES) by the Masters degree grant and Dr. Anna Sara Levin (Laboratório Investigação Médica-LIM-54 – Faculdade de Medicina da Universidade Federal de São Paulo) for supplying positive control strains.

REFERENCES

1. Tsai YK, Liou CH, Fung CP, Lin JC, Siu LK. Single or in combination antimicrobial resistance mechanisms of *Klebsiella pneumoniae* contribute to varied susceptibility to different carbapenems. *PLOS ONE*. 2013;8(11):e79640.
2. Nordmann P, Poirel L, Dortet L. Rapid detection of carbapenem-producing Enterobacteriaceae. *Emerg Infect Dis*. 2012;18:1503–1507.
3. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. *Clin Microbiol Infect*. 2014;20:821–830.
4. Cai JC, Hu YY, Zhang R, Chen GX. Detection of OmpK36 porin loss in *Klebsiella* spp. by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin Microbiol*. 2012;50:2179–2182.
5. Flinday J, Amouda A, Dancer SJ, Amyes SGB. Rapid acquisition of decreased carbapenem susceptibility in a strain of *Klebsiella pneumoniae* arising during meropenem therapy. *Clin Microbiol Infect*. 2012;18:140–146.
6. Panda A, Kurapati S, Samantaray JC, Srinivasan A, Khalil S. MALDI-TOF mass spectrometry proteomic based identification of clinical bacterial isolates. *Indian J Med Res*. 2014;140:770–777.
7. Clinical and laboratory standards institute (CLSI). *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard – Tenth Edition. M07-A10*. Wayne, PA: CLSI; 2015.
8. Lomaestro BM, Tobim EH, Shang W, Gootz T. The spread of *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* to upstate New York. *Clin Infect Dis*. 2006;43:26–28.
9. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn Microbiol Infect Dis*. 2011;70:119–123.
10. Nordmann P, Poirel L, Carrer A, Toleman MA, Walsh TR. How to detect NDM-1 producers. *J Clin Microbiol*. 2011;49:718–721.
11. Mendes RE, Kiyota KA, Monteiro J, et al. Rapid detection and identification of metallo-β-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. *J Clin Microbiol*. 2007;45:544–547.
12. Kim SY, Park YJ, Yu JK, et al. Prevalence and mechanisms of decreased susceptibility to carbapenems in *Klebsiella pneumoniae* isolates. *Diagn Microbiol Infect Dis*. 2007;57:85–91.
13. National Health Surveillance Agency (ANVISA). Technical Note on 01/2013. *Measures to Prevent and Control Infections by Multidrug-resistant Enterobacteriaceae*; 2013.
14. Tsakris A, Poulopoulos A, Pournaras S, et al. A simple phenotypic method for the differentiation of metallo-β-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. *J Antimicrob Chemother*. 2010;65:1664–1671.
15. Pires J, Novais A, Peixe L. Blue-Carba, an easy biochemical test for detection of diverse carbapenemase producers directly from bacterial cultures. *J Clin Microbiol*. 2013;51:4281–4283.
16. Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in *Pseudomonas aeruginosa*: novel agents for combination therapy. *Antimicrob Agents Chemother*. 2001;45:105–116.
17. Hernández-Allés S, Albertí S, Álvarez D, et al. Porin expression in clinical isolates of *Klebsiella pneumoniae*. *Microbiology*. 1999;145:673–679.
18. Rivera IG, Chowdhury MAR, Huq A, et al. Enterobacterial repetitive intergenic consensus sequences and the PCR to generate fingerprints of genomic DNAs from *Vibrio cholerae* O1, O139, and non-O1 strains. *Appl Environ Microbiol*. 1995;61:2898–2904.
19. Speijer HPHM, Savelkoul MJ, Bonten EE, et al. Application of different genotyping methods for *Pseudomonas aeruginosa* in a setting of endemicity in an intensive care unit. *J Clin Microbiol*. 1999;37:3654–3661.
20. Shanmugan P, Meenakshisundaram J, Jayaraman P. *bla_{KPC}* gene detection in clinical isolates of carbapenem resistant Enterobacteriaceae in a tertiary care hospital. *J Clin Diagn Res*. 2013;7:2736–2738.
21. Castanheira M, Costello AJ, Deshpande LM, Jones RN. Expansion of clonal complex 258 KPC-2-producing *Klebsiella pneumoniae* in Latin American hospitals: report of the SENTRY Antimicrobial Surveillance Program. *Antimicrob Agents Chemother*. 2012;56(3):1668–1669.
22. Pereira PS, de Araujo CFM, Seki LM, Zahner V, Carvalho-Assef APD, Asensi MD. Update of the molecular epidemiology of KPC-2-producing *Klebsiella pneumoniae* in Brazil: spread of clonal complex 11 (ST11, ST437 and ST340). *J Antimicrob Chemother*. 2013;68(2):312–316.
23. Andrade LN, Curiao T, Ferreira JC, et al. Dissemination of *bla_{KPC-2}* by the spread of *Klebsiella pneumoniae* clonal complex 258 clones (ST258 ST11 ST437) and plasmids (IncFII, IncN, IncL/M) among Enterobacteriaceae species in Brazil. *Antimicrob Agents Chemother*. 2011;55(7):3579–3583.
24. Song W, Hong SG, Yong D, et al. Combined use of the modified hodge test and carbapenemase inhibition test for detection of carbapenemase-producing Enterobacteriaceae

- and metallo- β -lactamase-producing *Pseudomonas* spp. *Ann Lab Med.* 2015;35:212–219.
- 25. Franklin C, Liolios L, Peleg AY. Phenotypic detection of carbapenem-susceptible metallo- β -lactamase-producing Gram-negative bacilli in the clinical laboratory. *J Clin Microbiol.* 2006;44:3139–3144.
 - 26. Chu YW, Cheung TKM, Ngan JYW, Kam KM. EDTA susceptibility leading to false detection of metallo- β -lactamase in *Pseudomonas aeruginosa* by Etest and an imipenem-EDTA disk method. *Int J Antimicrob Agents.* 2005;26:338–341.
 - 27. Franco MRG, Caiaffa-Filho HH, Burattini MN, Rossi F. Metallo-beta lactamases among imipenem-resistant *Pseudomonas aeruginosa* in a Brazilian university Hospital. *Clinics.* 2010;65:825–829.
 - 28. Khosravi Y, Loke MF, Chua EG, Tay ST, Vadivelu J. Phenotypic detection of metallo- β -lactamase in imipenem-resistant *Pseudomonas aeruginosa*. *Sci World J.* 2012;2012:1–7.
 - 29. García-Sureda L, Doménech-Sánchez A, Barbier M, Juan C, Gascó J, Albertí S. OmpK26, a novel porin associated with carbapenem resistance in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2014;(55):4742–4747.
 - 30. Shi W, Li K, Ji Y, et al. Carbapenem and cefoxitin resistance of *Klebsiella pneumoniae* strains associated with porin OmpK36 loss and DHA-1 β -lactamase production. *Braz J Microbiol.* 2013;44:435–442.
 - 31. Doménech-Sánchez A, Martínez-Martínez L, Hernández-Allés S, et al. Role of *Klebsiella pneumoniae* OmpK35 porin in antimicrobial resistance. *Antimicrob Agents Chemother.* 2003;47:3332–3335.